Rechercher des projets européens

14 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)

Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,

Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet

 26

 TERMINÉ 

"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" (EXALT)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,

"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Voir le projet

 7

 TERMINÉ 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet

 49

 TERMINÉ 

Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet

 30

 TERMINÉ 

The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease (DAVIAD)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2017,

This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbitopathy and children and adolescents (who generally suffer from the most chronic form of the disease). Autoimmune diseases ar ...
Voir le projet

 5

 TERMINÉ 

Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine (EbolaVac)

Date du début: 7 oct. 2014, Date de fin: 6 oct. 2017,

The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and e ...
Voir le projet

 5

 TERMINÉ 

Advanced Immunization Technologies (ADITEC)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet

 53

 TERMINÉ 

A Multi-Stage Malaria Vaccine (MultiMalVax)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life- ...
Voir le projet

 6

 TERMINÉ 

Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens (PEACHI)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,

"The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection. The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens.The PEACHI Consortium members have employed replication-defective simi ...
Voir le projet

 5

 TERMINÉ 

Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)

Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet

 24

 TERMINÉ 

Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses (ADJSYN)

Date du début: 1 juil. 2013, Date de fin: 30 juin 2015,

The need to develop vaccines against challenging diseases such as malaria or tuberculosis requires effective adjuvants to improve the immune responses against purified antigens, as these antigens often lack intrinsic immunogenicity. Most adjuvants act on innate immunity leading to the activation of antigen presenting cells and induction of memory T cell and antibody responses to the vaccine. Inclu ...
Voir le projet

 2

 TERMINÉ 

Exploring the roles and plasticity of T-cell responses in anti-BACterial immunity (T-BAC)

Date du début: 1 mai 2013, Date de fin: 30 avr. 2015,

"Antibodies against bacterial polysaccharides and proteins play a role in anti-bacterial immunity. To date, S. aureus vaccine candidates were selected to induce functional antibody responses. However, a potential role for T-cell mediated immunity is emerging, supported by the fact that impaired Th17 responses in patients with hyper IgE syndrome are linked to abnormal susceptibility to S. aureus in ...
Voir le projet

 2

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

System for Immunological Modelling as an Ultimate tool to Link Adjuvant function To Adaptive immune responses (SIMULATA)

Date du début: 2 juin 2010, Date de fin: 1 juin 2012,

"The aim of the proposal is to construct an in vitro model of human cellular immune responses and to address fundamental questions on the link between vaccine adjuvants and the adaptive immune response. One emerging concept of adjuvant-stimulated immune activation is that monocytes are recruited from the blood to the injection site and differentiate into either macrophages or dendritic cells (DCs) ...
Voir le projet

 2